Orion Porfolio Solutions LLC Sells 19,637 Shares of Hologic, Inc. $HOLX

by · The Markets Daily

Orion Porfolio Solutions LLC trimmed its stake in shares of Hologic, Inc. (NASDAQ:HOLX – Free Report) by 33.0% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 39,888 shares of the medical equipment provider’s stock after selling 19,637 shares during the quarter. Orion Porfolio Solutions LLC’s holdings in Hologic were worth $2,599,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors have also added to or reduced their stakes in the stock. Public Sector Pension Investment Board raised its holdings in Hologic by 4.1% during the 1st quarter. Public Sector Pension Investment Board now owns 30,452 shares of the medical equipment provider’s stock worth $1,881,000 after purchasing an additional 1,192 shares during the last quarter. Versor Investments LP raised its stake in Hologic by 37.3% during the first quarter. Versor Investments LP now owns 6,391 shares of the medical equipment provider’s stock worth $395,000 after buying an additional 1,736 shares during the last quarter. Fuller & Thaler Asset Management Inc. lifted its holdings in Hologic by 57.0% in the first quarter. Fuller & Thaler Asset Management Inc. now owns 35,575 shares of the medical equipment provider’s stock valued at $2,197,000 after buying an additional 12,910 shares during the period. BI Asset Management Fondsmaeglerselskab A S boosted its position in Hologic by 5.9% during the first quarter. BI Asset Management Fondsmaeglerselskab A S now owns 12,133 shares of the medical equipment provider’s stock valued at $749,000 after acquiring an additional 672 shares during the last quarter. Finally, Banco Bilbao Vizcaya Argentaria S.A. boosted its position in Hologic by 2.8% during the first quarter. Banco Bilbao Vizcaya Argentaria S.A. now owns 96,837 shares of the medical equipment provider’s stock valued at $5,982,000 after acquiring an additional 2,608 shares during the last quarter. 94.73% of the stock is currently owned by institutional investors.

Hologic Stock Up 0.0%

Shares of NASDAQ:HOLX opened at $74.94 on Friday. The company has a debt-to-equity ratio of 0.50, a quick ratio of 3.06 and a current ratio of 3.75. Hologic, Inc. has a 52-week low of $51.90 and a 52-week high of $75.34. The business’s 50 day simple moving average is $73.57 and its two-hundred day simple moving average is $68.64. The firm has a market cap of $16.70 billion, a P/E ratio of 30.22, a PEG ratio of 2.13 and a beta of 0.70.

Hologic (NASDAQ:HOLX – Get Free Report) last announced its quarterly earnings results on Monday, November 3rd. The medical equipment provider reported $1.13 EPS for the quarter, beating analysts’ consensus estimates of $1.10 by $0.03. Hologic had a net margin of 13.80% and a return on equity of 20.13%. The business had revenue of $1.05 billion during the quarter, compared to analyst estimates of $1.03 billion. During the same quarter in the previous year, the business posted $1.01 EPS. Hologic’s quarterly revenue was up 6.2% on a year-over-year basis. As a group, research analysts forecast that Hologic, Inc. will post 4.28 EPS for the current fiscal year.

Insider Activity

In related news, CEO Stephen P. Macmillan sold 138,358 shares of the firm’s stock in a transaction dated Monday, September 22nd. The shares were sold at an average price of $66.97, for a total value of $9,265,835.26. Following the transaction, the chief executive officer owned 1,234,624 shares of the company’s stock, valued at approximately $82,682,769.28. This trade represents a 10.08% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Christiana Stamoulis sold 7,402 shares of the business’s stock in a transaction that occurred on Monday, October 20th. The stock was sold at an average price of $73.07, for a total value of $540,864.14. Following the sale, the director directly owned 47,336 shares of the company’s stock, valued at $3,458,841.52. This represents a 13.52% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. 1.88% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

HOLX has been the subject of several research analyst reports. Wall Street Zen lowered Hologic from a “buy” rating to a “hold” rating in a research report on Wednesday, October 1st. Morgan Stanley lifted their target price on Hologic from $69.00 to $76.00 and gave the stock an “equal weight” rating in a report on Tuesday, November 11th. Evercore ISI set a $78.00 price target on Hologic and gave the company an “outperform” rating in a research note on Tuesday, October 7th. Argus increased their price target on Hologic from $80.00 to $90.00 and gave the stock a “buy” rating in a report on Friday, September 19th. Finally, Weiss Ratings reaffirmed a “hold (c)” rating on shares of Hologic in a research report on Friday, October 31st. Five analysts have rated the stock with a Buy rating and thirteen have assigned a Hold rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Hold” and an average price target of $79.29.

Get Our Latest Report on Hologic

About Hologic

(Free Report)

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.

Read More

Want to see what other hedge funds are holding HOLX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Hologic, Inc. (NASDAQ:HOLX – Free Report).